Researchers at St. Jude Children’s Research Hospital published a Lancet Microbe study showing that plasma microbial cell‑free DNA sequencing (mcfDNA‑Seq) can detect bloodstream infections in high‑risk pediatric leukemia patients days before clinical symptoms. The assay identified pathogens earlier than standard diagnostics, enabling potential pre‑emptive interventions. Early detection in immunocompromised children could reduce morbidity and guide targeted antimicrobial therapy, but integration into clinical workflows will require prospective validation, cost‑effectiveness analysis and demonstration that earlier detection improves outcomes. mcfDNA‑Seq analyzes circulating fragments of microbial DNA in plasma to identify pathogens noninvasively and with broad-range detection compared with culture‑based methods.